Clinical trials: Preclinical Alzheimer's Disease, active
Preclinical Alzheimer's Disease, Alzheimer Disease
AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease.
- Trial name
- AREVIA (NCT07827768)
- Testing
- AV-1959R
- Volunteers
- 160 people
- Sponsor
- Institute for Molecular Medicine
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Preclinical Alzheimer's Disease
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
- Trial name
- SPINOZA (NCT07794670)
- Testing
- Obicetrapib 10 mg
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- NewAmsterdam Pharma
Preclinical Alzheimer's Disease, Alzheimer Disease
Alzheimer's Tau Platform: Master Protocol
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late…
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Trial name
- ATP (NCT06957418)
- Testing
- AADvac1, Tau2
- Where
- 3 sites in United States
- Volunteers
- 900 people
- Sponsor
- Paul S. Aisen
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Alzheimer's Tau Platform: Regimen A - AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Trial name
- ATP (NCT07167966)
- Testing
- AADvac1, Donanemab
- Where
- 3 sites in United States
- Volunteers
- 450 people
- Sponsor
- Paul S. Aisen
Alzheimer Disease, Preclinical Alzheimer's Disease
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological…
- Trial name
- TAURUS-1980 (NCT07158905)
- Testing
- AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Institute for Molecular Medicine
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Alzheimer's Plasma Extension
The goal of this observational study is to learn how Alzheimer's disease-related blood biomarkers, brain amyloid, and memory and thinking abilities change over time.
- Trial name
- APEX (NCT06416072)
- Testing
- NAV4694
- Where
- 56 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial)…
- Trial name
- NCT04468659
- Testing
- Lecanemab
- Where
- 107 sites in United States, Australia and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eisai Inc.
Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease
TMS for Cognitive Decline in Aging and Preclinical AD
In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical…
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Trial name
- NCT06956300
- Testing
- Active rTMS
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer Disease, Preclinical Alzheimer
β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline
The overall (cross-sectional) objective of this study is to detect and describe the profile of AD-related blood biomarkers in a population with SCD (including individuals with MCI) with the ultimate goal of investigating their…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer, Mild Cognitive Impairment
- Trial name
- β-AARC (NCT04935372)
- Testing
- Observational
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation